Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Traumeel Plus Zeel an Emerging Alternative to Intra-Articular Steroids and Viscosupplement Injections for Pain Associated with Moderate to Severe Osteoarthritis of the Knee
  • USA - English


News provided by

MediNatura

Jun 16, 2015, 08:00 ET

Share this article

Share toX

Share this article

Share toX

MediNatura Inc.
MediNatura Inc.

The products’ unique approach and proven clinical efficacy offer an innovative treatment option to patients who are seeking clinically relevant but safe pain relief,” Stefan Luft, PhD, National Director of Sales and Medical Education, MediNatura.

Post this

PHILADELPHIA (PRWEB) June 16, 2015 -- According to analysis of the first ever double-blind trial of Traumeel and Zeel on moderate to severe osteoarthritis of the knee, this treatment showed efficacy effect sizes that were consistent with those observed for the widely used intra-articular injections of hyaluronic acid (HA viscosupplementation), corticosteroids, and oral NSAIDs.3,4 Unlike oral NSAIDs, the safety profile of this treatment was benign with no signals of cardiovascular, gastrointestinal, or other concerning risks.3,4 The analysis, which highlights the efficacy and excellent safety profile of this treatment, was presented at the annual meeting of the European League against Rheumatism (EULAR) in Rome, Italy. The presentation was made by Dr. Carlos Lozada of the University of Miami, who along with Dr. Roland Moskowitz of University Hospitals Case Medical Center, Cleveland, contributed to the study design.

Osteoarthritis (OA), a progressive disorder characterized by structural damage to joints, affects more than 600 million people worldwide and over 10 million adults in the US. Musculoskeletal conditions, including OA, are the second leading cause of disability worldwide. Individuals who are the most severely affected by OA are seniors and women over age 55.1

The vast majority of people with OA of the knee have at least one other chronic health condition, which can complicate the pharmacological treatment of pain related to OA due to the potential of drug-to-drug interactions and an increased risk of adverse events.1 Therefore, treatment approaches must be evaluated according to not only their efficacy compared to standard treatments, such as injected corticosteroids and oral NSAIDs, but also based on their risk-benefit ratio.

“We believe that our products will become an important treatment for physicians caring for patients with osteoarthritis of the knee,” said Stefan Luft, PhD, National Director of Sales and Medical Education, MediNatura™. “The products’ unique approach and proven clinical efficacy offer an innovative treatment option to patients who are seeking clinically relevant but safe pain relief.”

“These compounds have been available and used intra-articularly for a long time,” according to lead study author Carlos Lozada, MD, a rheumatologist in the University of Miami Health System. Among clinicians who have administered the treatment, the impression “has been that there was something there, but there were no double-blind data to support that,” he said, which was the rationale for the trial. “The study was undertaken to see if there was a true effect.”

The study enrolled 232 patients at 30 sites in the United States and was first presented at the recent annual meeting of the American College of Rheumatology (ACR). Eligible patients were men and women ages 45 to 80 with moderate-to-severe chronic knee osteoarthritis, based on both clinical and radiographic criteria, who were taking either an NSAID or acetaminophen for pain.4,5

Patients were randomized 1:1 to either Tr14 (Traumeel) plus Ze14 (Zeel) or a matching placebo, injected intra-articularly on days 1, 8, and 15, the standard injection schedule in clinical treatment. Patients were evaluated every 2 weeks.

On the primary endpoint, which involved the change from baseline on the knee subscale of the WOMAC A (Pain) Scale, treatment with Tr14/Ze14 performed significantly better than placebo beginning at day 15 (at the time of the final injection) and continuing through at all study visits except for day 29. The treatment’s superiority to the placebo was also seen in the secondary endpoint of pain following a 50 meter unassisted walk.5

Adverse events were generally mild and unrelated to treatment, Lozada said, and there were no treatment-related serious adverse events.2,4
References
1. http://oarsi.org/education/oarsi-resources/press-release-march-2014-updated-guidelines
2. Lozada, C., del Rio, E., Reitberg, DP., Smith, R., Kahn, C., and Moskowitz, RW. Arth Rheumat 66 (10) Suppl.: S1266 (Abstr 2896)
3. Bannuru et al. Ann Intern Med; 162: 1/6/15:p46-54
4. Lozada, C., del Rio, E., Reitberg, DP., Smith, R., Kahn, C., and Moskowitz, RW. Ann Rheum Dis 2015 EULAR. Abstract 4268
5. http://www.medscape.org/viewarticle/841173_5

About MediNatura™ Inc.
MediNatura™ Inc., is headquartered in greater Philadelphia and operates a factory and product development facility in Albuquerque, New Mexico. MediNatura™ provides effective Rx and OTC medicines that have exceptionally safe side-effect profiles. It does this by using active ingredients predominantly from natural sources. For more information on MediNatura™ and its products, please visit http://www.medinatura.com/pro

Call Weekdays 8.00am – 5pm MST (1-844-633-4628) or email info(at)MediNatura(dot)com

These statements have not been reviewed by the Food and Drug Administration. They are supported by traditional homeopathic principles.

Jessly raj, MediNatura, +1 (505) 363-0540, [email protected]

Modal title

Zeel Injection Solution
Zeel Injection Solution
Traumeel Injection Solution
Traumeel Injection Solution
Zeel Injection Solution Traumeel Injection Solution

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.